Categories: Entertainment

NYSE Content Advisory: Pre-Market Update + Fed decision & StubHub celebrates IPO

NEW YORK, Sept. 17, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on September 17th

- Advertisement -
  • Stocks are mixed this morning ahead of the Federal Reserve’s highly anticipated decision on interest rates this afternoon at 2 PM ET. Shortly thereafter, Chair Jerome Powell will deliver remarks
  • According to the latest data, traders are pricing in a more than 95% chance that the Federal Reserve will cut interest rates by 25-basis points to a range of 4.25%. This would mark the Fed’s first interest rate cut since last December.
  • Global online ticket marketplace StubHub celebrates its IPO today. On Tuesday, StubHub priced its IPO at $23.50 per share, valuing the company at $8.6 billion. It will begin trading under the ticker symbol STUB.

Opening Bell
StubHub (NYSE: STUB) celebrates its initial public offering

- Advertisement -

Closing Bell
Garmin (NYSE: GRMN) celebrates the 2025 Garmin Health Summit

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2775400/NYSE_Market_Update_Sept_17.mp4
Logo – https://mma.prnewswire.com/media/2581322/New_York_Stock_Exchange_Logo.jpg 

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–fed-decision–stubhub-celebrates-ipo-302559171.html

- Advertisement -
PRNW Agency

Recent Posts

Maha Songkran World Water Festival 2026 opens in Bangkok

Five days of culture, music and water celebrations at Benchakitti Park reinforce UNESCO-recognised Songkran as…

5 hours ago

BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase…

15 hours ago

Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency

Los Angeles, CA, April 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational…

15 hours ago

Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management

SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF),…

19 hours ago

CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands

BEIJING, April 11, 2026 /PRNewswire/ -- CGTN published an article on the meeting between Xi…

19 hours ago